Preferred Label : Allogeneic iPSC-derived Anti-CD19-CAR/IL-15-expressing NK Cells CNTY-101;
NCIt synonyms : Allogeneic Anti-CD19-CAR-iNK Cells CNTY-101; Allogeneic iPSC-derived Anti-CD19-CAR-CD28-CD3zeta-IL-15-expressing NK Cells CNTY-101; Allogeneic iPSC-derived Anti-CD19-CAR/IL-15-expressing Natural Killer Cells CNTY-101; Allogeneic Anti-CD19-CAR-iPSC-derived Natural Killer Cells CNTY-101;
NCIt definition : A preparation of allogeneic natural killer (NK) cells derived from a clonal master
induced pluripotent stem cell (iPSC) line, and engineered to express a chimeric antigen
receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) derived
from the anti-CD19 monoclonal antibody FMC63 and coupled to the CD28 and zeta chain
of the TCR/CD3 complex (CD3-zeta) costimulatory signaling domains, and interleukin
15 (IL-15), with potential immunostimulatory and antineoplastic activities. Upon administration,
allogeneic iPSC-derived anti-CD19-CAR/IL-15-expressing NK cells CNTY-101 recognize,
bind to and induce selective cytotoxicity in CD19-expressing tumor cells. IL-15 is
a pro-survival cytokine that promotes T-cell persistence and potentiates the immune
response against tumor cells. The human tumor associated antigen (TAA) CD19 is a B-cell
specific cell surface antigen expressed in all B-cell lineage malignancies. CNTY-101
is also engineered with a safety switch composed of a shorter version of the extracellular
domain of human epidermal growth factor receptor (EGFR). This allows the elimination
of CNTY-101 upon the administration of anti-EGFR antibodies such as cetuximab. In
addition, CNTY-101 is gene-edited to prevent its elimination by the patient's NK cells,
CD4 and CD8 T-cells.;
Molecule name : CNTY 101; CNTY-101;
NCI Metathesaurus CUI : CL1792248;
Origin ID : C187301;
UMLS CUI : C5706393;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
